<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01160289</url>
  </required_header>
  <id_info>
    <org_study_id>11888</org_study_id>
    <secondary_id>I4K-MC-GPEC</secondary_id>
    <nct_id>NCT01160289</nct_id>
  </id_info>
  <brief_title>A Study of LY900010 in Erectile Dysfunction</brief_title>
  <official_title>A Study of LY900010 (LY2452473 + Tadalafil) in the Treatment of Men With Erectile Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to compare the efficacy of LY2452473 + tadalafil to
      tadalafil alone in improving the erectile function (EF) of men with erectile dysfunction (ED)
      who incompletely respond to tadalafil alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF) Erectile Function (EF) Domain Score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The IIEF EF domain score was the sum of Questions (Q) 1 to Q5 and Q15 of the IIEF self-reported questionnaire. Q1 to Q5 were rated 0 (low/no EF) to 5 (high EF) and Q15 was rated 1 (no/low confidence) to 5 (high confidence). IIEF EF domain scores ranged from 1 to 30. Higher scores denoted better EF.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in the Percentage of &quot;Yes&quot; Responses on the Sexual Encounter Profile (SEP) Diary</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The SEP diary was a participant-assessed diary with 5 questions (Q): Q1 (erection achievement), Q2 (successful penetration), Q3 (successful intercourse), Q4 (satisfied with erection), and Q5 (satisfied with sexual experience) for each sexual encounter made over a specified period of time. SEP Q1 to Q5 scores were determined as a percentage of &quot;Yes&quot; responses to each of the 5 questions out of all sexual attempts recorded during the time period. A higher percentage of &quot;Yes&quot; responses indicated better EF. Assessed was the mean change from baseline in the percentage of &quot;Yes&quot; responses to the SEP diary Q1 to Q5. The least squares (LS) mean was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment*visit, baseline, baseline*treatment (if p-value &lt;0.25).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in IIEF Domain Scores (Intercourse Satisfaction, Orgasmic Function, Sexual Desire, and Overall Satisfaction)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Intercourse Satisfaction (IS) domain score: sum of Questions (Q) 6, Q7, and Q8, each rated 0 (low/no satisfaction) to 5 (high satisfaction). IS domain score range: 0 to 15; lower scores denoted lower satisfaction. Orgasmic Function (OF) domain score: sum of Q9 and Q10, each rated 0 (no sexual stimulation) to 5 (almost always/always). OF domain score range: 0 to 10; lower scores denoted lower OF. Sexual Desire (SD) domain score: sum of Q11 and Q12, each rated 1 (almost never or low/no sexual desire) to 5 (almost always or very high sexual desire). SD domain score range: 2 to 10; lower scores denoted lower SD. Overall Satisfaction (OS) domain score: sum of Q13 and Q14, each rated 1 (low/no satisfaction) to 5 (high satisfaction). OS domain score range: 2 to 10; lower scores denoted lower OS. Least squares (LS) mean estimated from repeated measures analysis of variance model that included terms for treatment, visit, treatment*visit, baseline, baseline*treatment (if p-value&lt;0.25).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in the Percentage of Participants Who Return to &quot;Normal&quot; on the International Index of Erectile Function (IIEF) Scale (EF&gt;25)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The percentage of participants whose IIEF Erectile Function (EF) domain scores changed from ≤25 at baseline to &gt;25 (normal) at Week 12. The IIEF EF domain score was the sum of IIEF Question (Q) 1 to Q5 and Q15. Q1 to Q5 were rated 0 (low/no EF) to 5 (high EF) and Q15 was rated 1 (no/low confidence) to 5 (high confidence). IIEF EF domain scores ranged from 1 to 30. Higher scores denoted better EF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in IIEF EF Domain Score Reported by Testosterone Concentration Subgroups</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The International Index of Erectile Function (IIEF) EF was the sum of Questions (Q) 1 to Q5 and Q15 of the IIEF Self-reported questionnaire. Q1 to Q5 were rated 0 (low/no erectile function) to 5 (high erectile function) and Q15 was rated 1 (no/low confidence) to 5 (high confidence). IIEF EF domain scores ranged from 1 to 30. Higher scores denoted better EF. Testosterone concentration subgroups were based on optimal baseline testosterone levels (&lt;340 nanograms per deciliter [ng/dL] or ≥340 ng/dL). The least squares (LS) mean was estimated from an analysis of covariance (ANCOVA) model that included terms for treatment group, baseline, and baseline*treatment interaction (if p-value&lt;0.25).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Prostate-Specific Antigen (PSA)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The least squares (LS) mean was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment*visit, baseline, baseline*treatment (if p-value&lt;0.25).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Total Cholesterol and Triglycerides</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The least squares (LS) mean was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment*visit, baseline, baseline*treatment (if p-value&lt;0.25).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to 12 Week Endpoint in High-Density Lipoprotein Cholesterol (HDL-C) and Low-Density Lipoprotein Cholesterol (LDL-C)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The least squares (LS) was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment*visit, baseline, baseline*treatment (if p-value&lt;0.25).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Fasting Glucose</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The least squares (LS) mean was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment*visit, baseline, baseline*treatment (if p-value&lt;0.25).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Fasting Insulin</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline to 12 Week endpoint in fasting blood insulin concentration. The least squares (LS) mean was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment*visit, baseline, baseline*treatment (if p-value&lt;0.25).</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">410</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>1 milligram (mg) LY2452473 + 5 mg tadalafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mg LY2452473 + 5 mg tadalafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mg LY2452473 + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg tadalafil + placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mg tadalafil + placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2452473</intervention_name>
    <description>Administered orally, once daily for 12 weeks</description>
    <arm_group_label>1 milligram (mg) LY2452473 + 5 mg tadalafil</arm_group_label>
    <arm_group_label>5 mg LY2452473 + 5 mg tadalafil</arm_group_label>
    <arm_group_label>5 mg LY2452473 + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tadalafil</intervention_name>
    <description>Administered orally, once daily for 12 weeks</description>
    <arm_group_label>1 milligram (mg) LY2452473 + 5 mg tadalafil</arm_group_label>
    <arm_group_label>10 mg tadalafil + placebo</arm_group_label>
    <arm_group_label>5 mg LY2452473 + 5 mg tadalafil</arm_group_label>
    <arm_group_label>5 mg tadalafil + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo (tadalafil)</intervention_name>
    <description>Administered orally, once daily for 12 weeks</description>
    <arm_group_label>1 milligram (mg) LY2452473 + 5 mg tadalafil</arm_group_label>
    <arm_group_label>10 mg tadalafil + placebo</arm_group_label>
    <arm_group_label>5 mg LY2452473 + 5 mg tadalafil</arm_group_label>
    <arm_group_label>5 mg LY2452473 + placebo</arm_group_label>
    <arm_group_label>5 mg tadalafil + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo (LY2452473)</intervention_name>
    <description>Administered orally, once daily for 12 weeks</description>
    <arm_group_label>10 mg tadalafil + placebo</arm_group_label>
    <arm_group_label>5 mg tadalafil + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria include:

          -  Ambulatory men

          -  History of erectile dysfunction of at least 3 months duration

          -  History of incomplete response to any phosphodiesterase type 5 inhibitor (PDE5i) at
             the maximum tolerated dose within the label

          -  Anticipate having the same female sexual partner throughout the duration of the study

          -  Are willing and able to make at least 4 sexual intercourse attempts with the female
             sexual partner during each 4-week segment of the study

          -  Agree to use birth control during the study and for 60 days after the study, unless
             the female partner is postmenopausal

          -  Agree not to use any other erectile dysfunction treatment, including herbal treatment,
             during the study and for 96 hours after the last dose of study drug

          -  Screening laboratory tests within normal limits except for testosterone

          -  Without a language barrier, are reliable and willing to follow study procedures

          -  Prostate-specific antigen (PSA) less than 10 nanograms per milliliter (ng/ml). Men
             with PSA greater than 4 and less than 10 ng/ml must have documentation of a negative
             histological biopsy of carcinoma of prostate within 12 months prior to screening

        Exclusion Criteria include:

          -  History of penile implant

          -  History of no response to injection therapy for erectile dysfunction

          -  History of radical prostatectomy or other pelvic surgery with subsequent failure to
             achieve any erection

          -  Exhibit the presence of clinically significant penile deformity in the opinion of the
             investigator

          -  History of prior sexual legal convictions

          -  Bilateral hip replacements

          -  History of cancer within the previous 5 years, except for excised superficial lesions
             such as basal cell carcinoma and squamous cell carcinoma of the skin

          -  Chronic stable angina currently treated with long-acting nitrates

          -  Chronic stable angina requiring treatment with short-acting nitrates within 90 days
             prior to screening

          -  Angina occurring during sexual intercourse in the 6 months prior to screening

          -  Unstable angina within 6 months prior to screening

          -  Myocardial infarction or coronary artery bypass graft surgery within 90 days prior to
             screening

          -  Angioplasty or stent placement within 90 days prior to screening

          -  Congestive heart failure within 6 months prior to screening

          -  History of sudden cardiac arrest

          -  Supraventricular arrhythmia with an uncontrolled ventricular response at rest, or any
             history of spontaneous or induced sustained ventricular tachycardia, or use an
             automatic internal cardioverter-defibrillator

          -  An abnormality in the 12-lead electrocardiogram (ECG) that in the opinion of the
             investigator places the subject in an unacceptable risk for study participation

          -  Systolic blood pressure greater than 170 or less than 90 millimeters of mercury (mm
             Hg) or diastolic blood pressure greater than 100 or less than 50 mm Hg at screening

          -  Hepatic, renal, human immunodeficiency virus (HIV), or clinically significant active
             neuropsychiatric disease

          -  History of central nervous system injuries (including stroke or spinal cord injury)
             within 6 months prior to screening

          -  Alcohol intake of 5 units or greater per day (1 unit = 12 ounces beer, 5 ounces wine,
             or 1.5 ounces of 80-proof distilled spirits)

          -  Receiving treatment with antiandrogens or 5-alpha reductase inhibitor

          -  Anabolic steroids, calcitonin, oral bisphosphonates, Vitamin D greater than 50,000
             international units per week (IU/week), dehydroepiandrosterone (DHEA), steroidal
             supplements, nutritional products intended to have weight reduction or performance
             enhancing effects, herbal supplements within 7 days prior to screening

          -  Currently treated with a potent cytochrome P450 (CYP) 3A4 inhibitor, such as systemic
             ketoconazole or ritonavir, or a CYP3A4 inducer such as rifampicin
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Glendora</city>
        <state>California</state>
        <zip>91741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vacaville</city>
        <state>California</state>
        <zip>95688</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Celebration</city>
        <state>Florida</state>
        <zip>34747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>33065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33317</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <zip>73034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <zip>98502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>July 8, 2010</study_first_submitted>
  <study_first_submitted_qc>July 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2010</study_first_posted>
  <results_first_submitted>March 11, 2019</results_first_submitted>
  <results_first_submitted_qc>March 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 9, 2019</results_first_posted>
  <disposition_first_submitted>February 10, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>February 10, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 14, 2012</disposition_first_posted>
  <last_update_submitted>March 11, 2019</last_update_submitted>
  <last_update_submitted_qc>March 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The study had 2 periods. Period 1: a screening, a 4-week washout, and a 4-week lead-in period prior to randomization. Period 2: a 12-week treatment and a 4-week follow-up period, post-randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Screened Subjects</title>
          <description>After screening but prior to randomization, subjects completed a 4-week washout and a 4-week tadalafil [5-milligram (mg) tablet, administered orally, once daily] lead-in period.</description>
        </group>
        <group group_id="P2">
          <title>1 mg LY2452473 and 5 mg Tadalafil</title>
          <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 1-mg capsule
tadalafil 5-mg tablet
placebo 10-mg tablet (matching tadalafil)</description>
        </group>
        <group group_id="P3">
          <title>5 mg LY2452473 and 5 mg Tadalafil</title>
          <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 5-mg capsule
tadalafil 5-mg tablet
placebo 10-mg tablet (matching tadalafil)</description>
        </group>
        <group group_id="P4">
          <title>5 mg LY2452473</title>
          <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 5-mg capsule
placebo 5-mg tablet (matching tadalafil)
placebo 10-mg tablet (matching tadalafil)</description>
        </group>
        <group group_id="P5">
          <title>10 mg Tadalafil</title>
          <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
tadalafil 10-mg tablet
placebo 5-mg capsule (matching LY2452473)
placebo 5-mg tablet (matching tadalafil)</description>
        </group>
        <group group_id="P6">
          <title>5 mg Tadalafil</title>
          <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
tadalafil 5-mg tablet
placebo 5-mg capsule (matching LY2452473)
placebo 10-mg tablet (matching tadalafil)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Screening, Washout, and Lead-In Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="894"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="410"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="484"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="308"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomization Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Post-Randomization Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="85"/>
                <participants group_id="P3" count="97"/>
                <participants group_id="P4" count="52"/>
                <participants group_id="P5" count="89"/>
                <participants group_id="P6" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="85"/>
                <participants group_id="P3" count="97"/>
                <participants group_id="P4" count="52"/>
                <participants group_id="P5" count="89"/>
                <participants group_id="P6" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="65"/>
                <participants group_id="P3" count="73"/>
                <participants group_id="P4" count="31"/>
                <participants group_id="P5" count="80"/>
                <participants group_id="P6" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>1 mg LY2452473 and 5 mg Tadalafil</title>
          <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 1-mg capsule
tadalafil 5-mg tablet
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
        </group>
        <group group_id="B2">
          <title>5 mg LY2452473 and 5 mg Tadalafil</title>
          <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 5-mg capsule
tadalafil 5-mg tablet
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
        </group>
        <group group_id="B3">
          <title>5 mg LY2452473</title>
          <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 5-mg capsule
placebo 5-mg tablet (matching tadalafil)
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
        </group>
        <group group_id="B4">
          <title>10 mg Tadalafil</title>
          <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
tadalafil 10-mg tablet
placebo 5-mg capsule (matching LY2452473)
placebo 5-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
        </group>
        <group group_id="B5">
          <title>5 mg Tadalafil</title>
          <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
tadalafil 5-mg tablet
placebo 5-mg capsule (matching LY2452473)
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="85"/>
            <count group_id="B2" value="97"/>
            <count group_id="B3" value="52"/>
            <count group_id="B4" value="89"/>
            <count group_id="B5" value="87"/>
            <count group_id="B6" value="410"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.7" spread="6.57"/>
                    <measurement group_id="B2" value="60.7" spread="6.57"/>
                    <measurement group_id="B3" value="58.7" spread="6.53"/>
                    <measurement group_id="B4" value="59.4" spread="6.54"/>
                    <measurement group_id="B5" value="60.5" spread="6.68"/>
                    <measurement group_id="B6" value="59.9" spread="6.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="89"/>
                    <measurement group_id="B5" value="87"/>
                    <measurement group_id="B6" value="410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="76"/>
                    <measurement group_id="B5" value="77"/>
                    <measurement group_id="B6" value="362"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="72"/>
                    <measurement group_id="B5" value="78"/>
                    <measurement group_id="B6" value="339"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="89"/>
                    <measurement group_id="B5" value="87"/>
                    <measurement group_id="B6" value="410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF) Erectile Function (EF) Domain Score</title>
        <description>The IIEF EF domain score was the sum of Questions (Q) 1 to Q5 and Q15 of the IIEF self-reported questionnaire. Q1 to Q5 were rated 0 (low/no EF) to 5 (high EF) and Q15 was rated 1 (no/low confidence) to 5 (high confidence). IIEF EF domain scores ranged from 1 to 30. Higher scores denoted better EF.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug [intention-to-treat (ITT) population] and had non-missing IIEF EF domain scores at baseline and at Week 12; Last observation carried forward (LOCF) applied to statistical analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg LY2452473 and 5 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 1-mg capsule
tadalafil 5-mg tablet
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O2">
            <title>5 mg LY2452473 and 5 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 5-mg capsule
tadalafil 5-mg tablet
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O3">
            <title>5 mg LY2452473</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 5-mg capsule
placebo 5-mg tablet (matching tadalafil)
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O4">
            <title>10 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
tadalafil 10-mg tablet
placebo 5-mg capsule (matching LY2452473)
placebo 5-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O5">
            <title>5 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
tadalafil 5-mg tablet
placebo 5-mg capsule (matching LY2452473)
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF) Erectile Function (EF) Domain Score</title>
          <description>The IIEF EF domain score was the sum of Questions (Q) 1 to Q5 and Q15 of the IIEF self-reported questionnaire. Q1 to Q5 were rated 0 (low/no EF) to 5 (high EF) and Q15 was rated 1 (no/low confidence) to 5 (high confidence). IIEF EF domain scores ranged from 1 to 30. Higher scores denoted better EF.</description>
          <population>Randomized participants who received at least 1 dose of study drug [intention-to-treat (ITT) population] and had non-missing IIEF EF domain scores at baseline and at Week 12; Last observation carried forward (LOCF) applied to statistical analyses.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="83"/>
                <count group_id="O5" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.515" spread="6.019" lower_limit="0.75" upper_limit="3.28"/>
                    <measurement group_id="O2" value="2.405" spread="6.920" lower_limit="0.88" upper_limit="3.27"/>
                    <measurement group_id="O3" value="-0.971" spread="6.699" lower_limit="0.7" upper_limit="3.27"/>
                    <measurement group_id="O4" value="3.530" spread="5.640"/>
                    <measurement group_id="O5" value="2.054" spread="4.800" lower_limit="0.7" upper_limit="3.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Only the treatment effects of 1 mg LY2452473 and 5 mg tadalafil versus 5 mg tadalafil and the treatment effects of 5 mg LY2452473 and 5 mg tadalafil versus 5 mg tadalafil were analyzed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5</p_value>
            <p_value_desc>The p-value was 1-sided and adjusted for multiple comparisons. The level of significance was 1-sided of 0.04.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment group (tx grp), baseline IIEF EF domain score, baseline testosterone level, tx grp*baseline IIEF, tx grp*testosterone level interactions.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Only the treatment effects of the treatment effects of 5 mg LY2452473 and 5 mg tadalafil versus 5 mg tadalafil and 1 mg LY2452473 and 5 mg tadalafil versus 5 mg tadalafil were analyzed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.498</p_value>
            <p_value_desc>The p-value was 1-sided and adjusted for multiple comparisons. The level of significance was 1-sided of 0.04.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The model included tx grp, baseline IIEF EF domain score, baseline testosterone level, tx grp*baseline IIEF, tx grp*testosterone level interactions.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in the Percentage of &quot;Yes&quot; Responses on the Sexual Encounter Profile (SEP) Diary</title>
        <description>The SEP diary was a participant-assessed diary with 5 questions (Q): Q1 (erection achievement), Q2 (successful penetration), Q3 (successful intercourse), Q4 (satisfied with erection), and Q5 (satisfied with sexual experience) for each sexual encounter made over a specified period of time. SEP Q1 to Q5 scores were determined as a percentage of &quot;Yes&quot; responses to each of the 5 questions out of all sexual attempts recorded during the time period. A higher percentage of &quot;Yes&quot; responses indicated better EF. Assessed was the mean change from baseline in the percentage of &quot;Yes&quot; responses to the SEP diary Q1 to Q5. The least squares (LS) mean was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment*visit, baseline, baseline*treatment (if p-value &lt;0.25).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug (ITT population) and had non-missing SEP diary data at baseline and at a post-baseline visit.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg LY2452473 and 5 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 1-mg capsule
tadalafil 5-mg tablet
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O2">
            <title>5 mg LY2452473 and 5 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 5-mg capsule
tadalafil 5-mg tablet
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O3">
            <title>5 mg LY2452473</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 5-mg capsule
placebo 5-mg tablet (matching tadalafil)
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O4">
            <title>10 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
tadalafil 10-mg tablet
placebo 5-mg capsule (matching LY2452473)
placebo 5-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O5">
            <title>5 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
tadalafil 5-mg tablet
placebo 5-mg capsule (matching LY2452473)
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in the Percentage of &quot;Yes&quot; Responses on the Sexual Encounter Profile (SEP) Diary</title>
          <description>The SEP diary was a participant-assessed diary with 5 questions (Q): Q1 (erection achievement), Q2 (successful penetration), Q3 (successful intercourse), Q4 (satisfied with erection), and Q5 (satisfied with sexual experience) for each sexual encounter made over a specified period of time. SEP Q1 to Q5 scores were determined as a percentage of &quot;Yes&quot; responses to each of the 5 questions out of all sexual attempts recorded during the time period. A higher percentage of &quot;Yes&quot; responses indicated better EF. Assessed was the mean change from baseline in the percentage of &quot;Yes&quot; responses to the SEP diary Q1 to Q5. The least squares (LS) mean was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment*visit, baseline, baseline*treatment (if p-value &lt;0.25).</description>
          <population>Randomized participants who received at least 1 dose of study drug (ITT population) and had non-missing SEP diary data at baseline and at a post-baseline visit.</population>
          <units>percentage of &quot;yes&quot; responses</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Question 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.247" spread="2.378"/>
                    <measurement group_id="O2" value="-2.976" spread="2.295"/>
                    <measurement group_id="O3" value="-10.711" spread="3.268"/>
                    <measurement group_id="O4" value="4.427" spread="2.168"/>
                    <measurement group_id="O5" value="-1.425" spread="2.305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.175" spread="3.345"/>
                    <measurement group_id="O2" value="3.689" spread="3.227"/>
                    <measurement group_id="O3" value="-7.849" spread="4.566"/>
                    <measurement group_id="O4" value="10.267" spread="3.064"/>
                    <measurement group_id="O5" value="1.844" spread="3.240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.296" spread="3.808"/>
                    <measurement group_id="O2" value="11.752" spread="3.675"/>
                    <measurement group_id="O3" value="-3.800" spread="5.195"/>
                    <measurement group_id="O4" value="14.645" spread="3.489"/>
                    <measurement group_id="O5" value="2.593" spread="3.688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.935" spread="3.998"/>
                    <measurement group_id="O2" value="13.910" spread="3.854"/>
                    <measurement group_id="O3" value="-1.570" spread="5.454"/>
                    <measurement group_id="O4" value="24.202" spread="3.656"/>
                    <measurement group_id="O5" value="8.857" spread="3.872"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.602" spread="4.027"/>
                    <measurement group_id="O2" value="15.196" spread="3.880"/>
                    <measurement group_id="O3" value="-1.956" spread="5.488"/>
                    <measurement group_id="O4" value="22.410" spread="3.683"/>
                    <measurement group_id="O5" value="9.400" spread="3.897"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.722</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the percentage of &quot;Yes&quot; responses on the SEP diary, Q1; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>1.178</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.312</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.634</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the percentage of &quot;Yes&quot; responses on the SEP diary, Q1; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-1.552</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.253</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.147</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the percentage of &quot;Yes&quot; responses on the SEP diary, Q1; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-4.674</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.218</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the percentage of &quot;Yes&quot; responses on the SEP diary, Q1; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-7.404</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.157</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.775</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the percentage of &quot;Yes&quot; responses on the SEP diary, Q2; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>1.330</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.658</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.687</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the percentage of &quot;Yes&quot; responses on the SEP diary, Q2; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>1.844</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.573</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.119</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the percentage of &quot;Yes&quot; responses on the SEP diary, Q2; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-7.092</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.535</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.140</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the percentage of &quot;Yes&quot; responses on the SEP diary, Q2; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-6.578</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.450</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.207</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the percentage of &quot;Yes&quot; responses on the SEP diary, Q3; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>6.703</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.302</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.079</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the percentage of &quot;Yes&quot; responses on the SEP diary, Q3; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>9.159</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.206</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.301</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the percentage of &quot;Yes&quot; responses on the SEP diary, Q3; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-5.349</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.165</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.568</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the percentage of &quot;Yes&quot; responses on the SEP diary, Q3; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-2.893</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.067</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.464</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the percentage of &quot;Yes&quot; responses on the SEP diary, Q4; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>4.079</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.566</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.356</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the percentage of &quot;Yes&quot; responses on the SEP diary, Q4; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>5.054</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.463</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.038</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the percentage of &quot;Yes&quot; responses on the SEP diary, Q4; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-11.266</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.418</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.054</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the percentage of &quot;Yes&quot; responses on the SEP diary, Q4; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-10.292</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.312</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.454</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the percentage of &quot;Yes&quot; responses on the SEP diary, Q5; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>4.202</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.603</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.293</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the percentage of &quot;Yes&quot; responses on the SEP diary, Q5; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>5.796</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.499</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.107</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the percentage of &quot;Yes&quot; responses on the SEP diary, Q5; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-8.808</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.457</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.178</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the percentage of &quot;Yes&quot; responses on the SEP diary, Q5; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-7.214</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.349</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in IIEF Domain Scores (Intercourse Satisfaction, Orgasmic Function, Sexual Desire, and Overall Satisfaction)</title>
        <description>Intercourse Satisfaction (IS) domain score: sum of Questions (Q) 6, Q7, and Q8, each rated 0 (low/no satisfaction) to 5 (high satisfaction). IS domain score range: 0 to 15; lower scores denoted lower satisfaction. Orgasmic Function (OF) domain score: sum of Q9 and Q10, each rated 0 (no sexual stimulation) to 5 (almost always/always). OF domain score range: 0 to 10; lower scores denoted lower OF. Sexual Desire (SD) domain score: sum of Q11 and Q12, each rated 1 (almost never or low/no sexual desire) to 5 (almost always or very high sexual desire). SD domain score range: 2 to 10; lower scores denoted lower SD. Overall Satisfaction (OS) domain score: sum of Q13 and Q14, each rated 1 (low/no satisfaction) to 5 (high satisfaction). OS domain score range: 2 to 10; lower scores denoted lower OS. Least squares (LS) mean estimated from repeated measures analysis of variance model that included terms for treatment, visit, treatment*visit, baseline, baseline*treatment (if p-value&lt;0.25).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug (ITT population) and had non-missing IIEF domain scores at baseline and at a post-baseline visit.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg LY2452473 and 5 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 1-mg capsule
tadalafil 5-mg tablet
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O2">
            <title>5 mg LY2452473 and 5 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 5-mg capsule
tadalafil 5-mg tablet
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O3">
            <title>5 mg LY2452473</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 5-mg capsule
placebo 5-mg tablet (matching tadalafil)
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O4">
            <title>10 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
tadalafil 10-mg tablet
placebo 5-mg capsule (matching LY2452473)
placebo 5-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O5">
            <title>5 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
tadalafil 5-mg tablet
placebo 5-mg capsule (matching LY2452473)
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in IIEF Domain Scores (Intercourse Satisfaction, Orgasmic Function, Sexual Desire, and Overall Satisfaction)</title>
          <description>Intercourse Satisfaction (IS) domain score: sum of Questions (Q) 6, Q7, and Q8, each rated 0 (low/no satisfaction) to 5 (high satisfaction). IS domain score range: 0 to 15; lower scores denoted lower satisfaction. Orgasmic Function (OF) domain score: sum of Q9 and Q10, each rated 0 (no sexual stimulation) to 5 (almost always/always). OF domain score range: 0 to 10; lower scores denoted lower OF. Sexual Desire (SD) domain score: sum of Q11 and Q12, each rated 1 (almost never or low/no sexual desire) to 5 (almost always or very high sexual desire). SD domain score range: 2 to 10; lower scores denoted lower SD. Overall Satisfaction (OS) domain score: sum of Q13 and Q14, each rated 1 (low/no satisfaction) to 5 (high satisfaction). OS domain score range: 2 to 10; lower scores denoted lower OS. Least squares (LS) mean estimated from repeated measures analysis of variance model that included terms for treatment, visit, treatment*visit, baseline, baseline*treatment (if p-value&lt;0.25).</description>
          <population>Randomized participants who received at least 1 dose of study drug (ITT population) and had non-missing IIEF domain scores at baseline and at a post-baseline visit.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Intercourse Satisfaction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.475" spread="0.340"/>
                    <measurement group_id="O2" value="0.514" spread="0.322"/>
                    <measurement group_id="O3" value="-0.672" spread="0.463"/>
                    <measurement group_id="O4" value="1.127" spread="0.310"/>
                    <measurement group_id="O5" value="0.554" spread="0.327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Orgasmic Function</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.510" spread="0.289"/>
                    <measurement group_id="O2" value="0.117" spread="0.274"/>
                    <measurement group_id="O3" value="0.160" spread="0.394"/>
                    <measurement group_id="O4" value="0.678" spread="0.264"/>
                    <measurement group_id="O5" value="0.733" spread="0.278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexual Desire</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.092" spread="0.186"/>
                    <measurement group_id="O2" value="0.001" spread="0.176"/>
                    <measurement group_id="O3" value="-0.201" spread="0.253"/>
                    <measurement group_id="O4" value="0.392" spread="0.169"/>
                    <measurement group_id="O5" value="0.180" spread="0.178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Satisfaction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.477" spread="0.247"/>
                    <measurement group_id="O2" value="0.258" spread="0.235"/>
                    <measurement group_id="O3" value="-0.378" spread="0.339"/>
                    <measurement group_id="O4" value="1.206" spread="0.226"/>
                    <measurement group_id="O5" value="0.826" spread="0.238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.867</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the IIEF IS domain score; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-0.079</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.472</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.931</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the IIEF IS domain score; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-0.039</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.458</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.158</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the IIEF IS domain score; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-0.652</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.460</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.172</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the IIEF IS domain score; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-0.612</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.447</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.579</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the IIEF OF domain score; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-0.223</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.401</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.115</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the IIEF OF domain score; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-0.616</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.390</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.668</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the IIEF OF domain score; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-0.168</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.392</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.141</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the IIEF OF domain score; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-0.561</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.380</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.734</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the IIEF SD domain score; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-0.088</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.258</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.477</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the IIEF SD domain score; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-0.179</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.251</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.235</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the IIEF SD domain score; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-0.300</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.252</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.111</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the IIEF SD domain score; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-0.391</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.245</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.310</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the IIEF OS domain score; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-0.349</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.343</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.090</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the IIEF OS domain score; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-0.568</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.334</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.030</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the IIEF OS domain score; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-0.729</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.335</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the IIEF OS domain score; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-0.948</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.326</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in the Percentage of Participants Who Return to &quot;Normal&quot; on the International Index of Erectile Function (IIEF) Scale (EF&gt;25)</title>
        <description>The percentage of participants whose IIEF Erectile Function (EF) domain scores changed from ≤25 at baseline to &gt;25 (normal) at Week 12. The IIEF EF domain score was the sum of IIEF Question (Q) 1 to Q5 and Q15. Q1 to Q5 were rated 0 (low/no EF) to 5 (high EF) and Q15 was rated 1 (no/low confidence) to 5 (high confidence). IIEF EF domain scores ranged from 1 to 30. Higher scores denoted better EF.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug (ITT population).</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg LY2452473 and 5 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 1-mg capsule
tadalafil 5-mg tablet
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O2">
            <title>5 mg LY2452473 and 5 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 5-mg capsule
tadalafil 5-mg tablet
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O3">
            <title>5 mg LY2452473</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 5-mg capsule
placebo 5-mg tablet (matching tadalafil)
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O4">
            <title>10 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
tadalafil 10-mg tablet
placebo 5-mg capsule (matching LY2452473)
placebo 5-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O5">
            <title>5 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
tadalafil 5-mg tablet
placebo 5-mg capsule (matching LY2452473)
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in the Percentage of Participants Who Return to &quot;Normal&quot; on the International Index of Erectile Function (IIEF) Scale (EF&gt;25)</title>
          <description>The percentage of participants whose IIEF Erectile Function (EF) domain scores changed from ≤25 at baseline to &gt;25 (normal) at Week 12. The IIEF EF domain score was the sum of IIEF Question (Q) 1 to Q5 and Q15. Q1 to Q5 were rated 0 (low/no EF) to 5 (high EF) and Q15 was rated 1 (no/low confidence) to 5 (high confidence). IIEF EF domain scores ranged from 1 to 30. Higher scores denoted better EF.</description>
          <population>Randomized participants who received at least 1 dose of study drug (ITT population).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.7"/>
                    <measurement group_id="O2" value="27.8"/>
                    <measurement group_id="O3" value="13.5"/>
                    <measurement group_id="O4" value="30.3"/>
                    <measurement group_id="O5" value="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in IIEF EF Domain Score Reported by Testosterone Concentration Subgroups</title>
        <description>The International Index of Erectile Function (IIEF) EF was the sum of Questions (Q) 1 to Q5 and Q15 of the IIEF Self-reported questionnaire. Q1 to Q5 were rated 0 (low/no erectile function) to 5 (high erectile function) and Q15 was rated 1 (no/low confidence) to 5 (high confidence). IIEF EF domain scores ranged from 1 to 30. Higher scores denoted better EF. Testosterone concentration subgroups were based on optimal baseline testosterone levels (&lt;340 nanograms per deciliter [ng/dL] or ≥340 ng/dL). The least squares (LS) mean was estimated from an analysis of covariance (ANCOVA) model that included terms for treatment group, baseline, and baseline*treatment interaction (if p-value&lt;0.25).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug (ITT population) and had non-missing IIEF EF domain scores at baseline and at a post-baseline visit; Last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg LY2452473 and 5 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 1-mg capsule
tadalafil 5-mg tablet
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O2">
            <title>5 mg LY2452473 and 5 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 5-mg capsule
tadalafil 5-mg tablet
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O3">
            <title>5 mg LY2452473</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 5-mg capsule
placebo 5-mg tablet (matching tadalafil)
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O4">
            <title>10 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
tadalafil 10-mg tablet
placebo 5-mg capsule (matching LY2452473)
placebo 5-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O5">
            <title>5 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
tadalafil 5-mg tablet
placebo 5-mg capsule (matching LY2452473)
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in IIEF EF Domain Score Reported by Testosterone Concentration Subgroups</title>
          <description>The International Index of Erectile Function (IIEF) EF was the sum of Questions (Q) 1 to Q5 and Q15 of the IIEF Self-reported questionnaire. Q1 to Q5 were rated 0 (low/no erectile function) to 5 (high erectile function) and Q15 was rated 1 (no/low confidence) to 5 (high confidence). IIEF EF domain scores ranged from 1 to 30. Higher scores denoted better EF. Testosterone concentration subgroups were based on optimal baseline testosterone levels (&lt;340 nanograms per deciliter [ng/dL] or ≥340 ng/dL). The least squares (LS) mean was estimated from an analysis of covariance (ANCOVA) model that included terms for treatment group, baseline, and baseline*treatment interaction (if p-value&lt;0.25).</description>
          <population>Randomized participants who received at least 1 dose of study drug (ITT population) and had non-missing IIEF EF domain scores at baseline and at a post-baseline visit; Last observation carried forward (LOCF).</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone &lt;340 ng/dL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="28"/>
                    <count group_id="O4" value="54"/>
                    <count group_id="O5" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.523" spread="0.952"/>
                    <measurement group_id="O2" value="1.012" spread="0.848"/>
                    <measurement group_id="O3" value="-1.055" spread="1.223"/>
                    <measurement group_id="O4" value="4.172" spread="0.852"/>
                    <measurement group_id="O5" value="1.935" spread="0.912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Testosterone ≥340 ng/dL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.077" spread="1.019"/>
                    <measurement group_id="O2" value="3.416" spread="1.071"/>
                    <measurement group_id="O3" value="-0.714" spread="1.387"/>
                    <measurement group_id="O4" value="2.217" spread="1.070"/>
                    <measurement group_id="O5" value="1.703" spread="1.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.656</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the IIEF EF domain scores reported by optimal testosterone level &lt;340 ng/dL; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.460</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the IIEF EF domain scores reported by optimal testosterone level &lt;340 ng/dL; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.198</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the IIEF EF domain scores reported by optimal testosterone level &lt;340 ng/dL; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the IIEF EF domain scores reported by optimal testosterone level ≥340 ng/dL; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.671</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the IIEF EF domain scores reported by optimal testosterone level ≥340 ng/dL; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.259</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the IIEF EF domain scores reported by optimal testosterone level ≥340 ng/dL; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.441</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the IIEF EF domain scores reported by optimal testosterone level ≥340 ng/dL; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.433</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in the IIEF EF domain scores reported by optimal testosterone level ≥340 ng/dL; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Prostate-Specific Antigen (PSA)</title>
        <description>The least squares (LS) mean was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment*visit, baseline, baseline*treatment (if p-value&lt;0.25).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug (ITT population) and had non-missing PSA data at baseline and at a post-baseline visit.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg LY2452473 and 5 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 1-mg capsule
tadalafil 5-mg tablet
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O2">
            <title>5 mg LY2452473 and 5 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 5-mg capsule
tadalafil 5-mg tablet
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O3">
            <title>5 mg LY2452473</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 5-mg capsule
placebo 5-mg tablet (matching tadalafil)
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O4">
            <title>10 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
tadalafil 10-mg tablet
placebo 5-mg capsule (matching LY2452473)
placebo 5-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O5">
            <title>5 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
tadalafil 5-mg tablet
placebo 5-mg capsule (matching LY2452473)
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Prostate-Specific Antigen (PSA)</title>
          <description>The least squares (LS) mean was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment*visit, baseline, baseline*treatment (if p-value&lt;0.25).</description>
          <population>Randomized participants who received at least 1 dose of study drug (ITT population) and had non-missing PSA data at baseline and at a post-baseline visit.</population>
          <units>nanograms per milliliter (ng/mL)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="87"/>
                <count group_id="O5" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.162" spread="0.119"/>
                    <measurement group_id="O2" value="-0.088" spread="0.109"/>
                    <measurement group_id="O3" value="0.265" spread="0.157"/>
                    <measurement group_id="O4" value="0.246" spread="0.107"/>
                    <measurement group_id="O5" value="0.032" spread="0.111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.423</p_value>
            <p_value_desc>Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>0.130</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.443</p_value>
            <p_value_desc>Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-0.120</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.599</p_value>
            <p_value_desc>Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-0.084</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <p_value_desc>Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-0.334</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Total Cholesterol and Triglycerides</title>
        <description>The least squares (LS) mean was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment*visit, baseline, baseline*treatment (if p-value&lt;0.25).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug (ITT population) and had non-missing laboratory data (total cholesterol and triglycerides) at baseline and at a post-baseline visit.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg LY2452473 and 5 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 1-mg capsule
tadalafil 5-mg tablet
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O2">
            <title>5 mg LY2452473 and 5 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 5-mg capsule
tadalafil 5-mg tablet
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O3">
            <title>5 mg LY2452473</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 5-mg capsule
placebo 5-mg tablet (matching tadalafil)
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O4">
            <title>10 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
tadalafil 10-mg tablet
placebo 5-mg capsule (matching LY2452473)
placebo 5-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O5">
            <title>5 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
tadalafil 5-mg tablet
placebo 5-mg capsule (matching LY2452473)
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Total Cholesterol and Triglycerides</title>
          <description>The least squares (LS) mean was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment*visit, baseline, baseline*treatment (if p-value&lt;0.25).</description>
          <population>Randomized participants who received at least 1 dose of study drug (ITT population) and had non-missing laboratory data (total cholesterol and triglycerides) at baseline and at a post-baseline visit.</population>
          <units>millimoles per Liter (mmol/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.210" spread="0.076"/>
                    <measurement group_id="O2" value="-0.275" spread="0.071"/>
                    <measurement group_id="O3" value="-0.282" spread="0.102"/>
                    <measurement group_id="O4" value="-0.086" spread="0.069"/>
                    <measurement group_id="O5" value="-0.059" spread="0.072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.155" spread="0.070"/>
                    <measurement group_id="O2" value="-0.171" spread="0.066"/>
                    <measurement group_id="O3" value="-0.067" spread="0.096"/>
                    <measurement group_id="O4" value="-0.139" spread="0.063"/>
                    <measurement group_id="O5" value="0.056" spread="0.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.148</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in total cholesterol; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS Mean of treatment difference</param_type>
            <param_value>-0.152</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.033</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in total cholesterol; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-0.216</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.224</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in total cholesterol; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-0.124</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.056</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in total cholesterol; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-0.189</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.031</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in triglycerides; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-0.211</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in triglycerides; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-0.227</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.866</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in triglycerides; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-0.016</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.726</p_value>
            <p_value_desc>The p-value is for the change from baseline to Week 12 in triglycerides; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-0.032</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to 12 Week Endpoint in High-Density Lipoprotein Cholesterol (HDL-C) and Low-Density Lipoprotein Cholesterol (LDL-C)</title>
        <description>The least squares (LS) was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment*visit, baseline, baseline*treatment (if p-value&lt;0.25).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug (ITT population) and had non-missing laboratory data (HDL-C and LDL-C) at baseline and at a post-baseline visit.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg LY2452473 and 5 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 1-mg capsule
tadalafil 5-mg tablet
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O2">
            <title>5 mg LY2452473 and 5 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 5-mg capsule
tadalafil 5-mg tablet
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O3">
            <title>5 mg LY2452473</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 5-mg capsule
placebo 5-mg tablet (matching tadalafil)
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O4">
            <title>10 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
tadalafil 10-mg tablet
placebo 5-mg capsule (matching LY2452473)
placebo 5-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O5">
            <title>5 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
tadalafil 5-mg tablet
placebo 5-mg capsule (matching LY2452473)
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to 12 Week Endpoint in High-Density Lipoprotein Cholesterol (HDL-C) and Low-Density Lipoprotein Cholesterol (LDL-C)</title>
          <description>The least squares (LS) was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment*visit, baseline, baseline*treatment (if p-value&lt;0.25).</description>
          <population>Randomized participants who received at least 1 dose of study drug (ITT population) and had non-missing laboratory data (HDL-C and LDL-C) at baseline and at a post-baseline visit.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.440" spread="1.658"/>
                    <measurement group_id="O2" value="-16.974" spread="1.556"/>
                    <measurement group_id="O3" value="-22.230" spread="2.243"/>
                    <measurement group_id="O4" value="1.776" spread="1.505"/>
                    <measurement group_id="O5" value="1.573" spread="1.585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.695" spread="2.479"/>
                    <measurement group_id="O2" value="0.062" spread="2.319"/>
                    <measurement group_id="O3" value="-3.424" spread="3.365"/>
                    <measurement group_id="O4" value="-0.066" spread="2.245"/>
                    <measurement group_id="O5" value="-0.718" spread="2.367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The p-value is for the percent change from baseline to Week 12 in HDL-C; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS Mean of treatment difference</param_type>
            <param_value>-9.014</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The p-value is for the percent change from baseline to Week 12 in HDL-C; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-18.547</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The p-value is for the percent change from baseline to Week 12 in HDL-C; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-9.216</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The p-value is for the percent change from baseline to Week 12 in HDL-C; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-18.750</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.776</p_value>
            <p_value_desc>The p-value is for the percent change from baseline to Week 12 in LDL-C; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-0.977</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.814</p_value>
            <p_value_desc>The p-value is for the percent change from baseline to Week 12 in LDL-C; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>0.780</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.627</p_value>
            <p_value_desc>The p-value is for the percent change from baseline to Week 12 in LDL-C; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-1.629</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.968</p_value>
            <p_value_desc>The p-value is for the percent change from baseline to Week 12 in LDL-C; Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>0.128</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Fasting Glucose</title>
        <description>The least squares (LS) mean was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment*visit, baseline, baseline*treatment (if p-value&lt;0.25).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug (ITT population) and had non-missing laboratory data (fasting glucose) at baseline and at a post-baseline visit.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg LY2452473 and 5 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 1-mg capsule
tadalafil 5-mg tablet
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O2">
            <title>5 mg LY2452473 and 5 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 5-mg capsule
tadalafil 5-mg tablet
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O3">
            <title>5 mg LY2452473</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 5-mg capsule
placebo 5-mg tablet (matching tadalafil)
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O4">
            <title>10 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
tadalafil 10-mg tablet
placebo 5-mg capsule (matching LY2452473)
placebo 5-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O5">
            <title>5 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
tadalafil 5-mg tablet
placebo 5-mg capsule (matching LY2452473)
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Fasting Glucose</title>
          <description>The least squares (LS) mean was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment*visit, baseline, baseline*treatment (if p-value&lt;0.25).</description>
          <population>All randomized participants who received at least 1 dose of study drug (ITT population) and had non-missing laboratory data (fasting glucose) at baseline and at a post-baseline visit.</population>
          <units>millimoles per Liter (mmol/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.153" spread="0.195"/>
                    <measurement group_id="O2" value="-0.306" spread="0.183"/>
                    <measurement group_id="O3" value="0.070" spread="0.268"/>
                    <measurement group_id="O4" value="-0.234" spread="0.176"/>
                    <measurement group_id="O5" value="0.158" spread="0.186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.984</p_value>
            <p_value_desc>Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS Mean of treatment difference</param_type>
            <param_value>-0.006</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.076</p_value>
            <p_value_desc>Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-0.465</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.142</p_value>
            <p_value_desc>Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>0.387</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.776</p_value>
            <p_value_desc>Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-0.072</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Fasting Insulin</title>
        <description>Change from baseline to 12 Week endpoint in fasting blood insulin concentration. The least squares (LS) mean was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment*visit, baseline, baseline*treatment (if p-value&lt;0.25).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug (ITT population) and had non-missing laboratory data (fasting insulin) at baseline and at a post-baseline visit.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg LY2452473 and 5 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 1-mg capsule
tadalafil 5-mg tablet
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O2">
            <title>5 mg LY2452473 and 5 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 5-mg capsule
tadalafil 5-mg tablet
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O3">
            <title>5 mg LY2452473</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 5-mg capsule
placebo 5-mg tablet (matching tadalafil)
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O4">
            <title>10 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
tadalafil 10-mg tablet
placebo 5-mg capsule (matching LY2452473)
placebo 5-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
          <group group_id="O5">
            <title>5 mg Tadalafil</title>
            <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
tadalafil 5-mg tablet
placebo 5-mg capsule (matching LY2452473)
placebo 10-mg tablet (matching tadalafil)
Prior to randomization, participants successfully completed a 4-week washout period and a 4-week tadalafil (5-mg tablet, daily) lead-in period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Fasting Insulin</title>
          <description>Change from baseline to 12 Week endpoint in fasting blood insulin concentration. The least squares (LS) mean was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment*visit, baseline, baseline*treatment (if p-value&lt;0.25).</description>
          <population>Randomized participants who received at least 1 dose of study drug (ITT population) and had non-missing laboratory data (fasting insulin) at baseline and at a post-baseline visit.</population>
          <units>milliunits per Liter (mU/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.756" spread="2.235"/>
                    <measurement group_id="O2" value="-4.501" spread="2.075"/>
                    <measurement group_id="O3" value="-0.717" spread="3.068"/>
                    <measurement group_id="O4" value="-3.300" spread="1.976"/>
                    <measurement group_id="O5" value="-1.276" spread="2.109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.103</p_value>
            <p_value_desc>Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS Mean of treatment difference</param_type>
            <param_value>5.031</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.277</p_value>
            <p_value_desc>Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean treatment difference</param_type>
            <param_value>-3.225</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <p_value_desc>Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>7.056</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.676</p_value>
            <p_value_desc>Conducted at a 2-sided alpha level of 0.10 without adjustment for multiplicity.</p_value_desc>
            <method>Mixed model repeated measures analysis</method>
            <param_type>LS mean of treatment difference</param_type>
            <param_value>-1.201</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>5 mg Tadalafil, Lead-in Period</title>
          <description>5-mg tadalafil tablet, administered orally, once daily, during the 4-week lead-in period.</description>
        </group>
        <group group_id="E2">
          <title>1 mg LY2452473 and 5 mg Tadalafil</title>
          <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 1-mg capsule
tadalafil 5-mg tablet
placebo 10-mg tablet (matching tadalafil)</description>
        </group>
        <group group_id="E3">
          <title>5 mg LY2452473 and 5 mg Tadalafil</title>
          <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 5-mg capsule
tadalafil 5-mg tablet
placebo 10-mg tablet (matching tadalafil)</description>
        </group>
        <group group_id="E4">
          <title>5 mg LY2452473</title>
          <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
LY2452473 5-mg capsule
placebo 5-mg tablet (matching tadalafil)
placebo 10-mg tablet (matching tadalafil)</description>
        </group>
        <group group_id="E5">
          <title>10 mg Tadalafil</title>
          <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
tadalafil 10-mg tablet
placebo 5-mg capsule (matching LY2452473)
placebo 5-mg tablet (matching tadalafil)</description>
        </group>
        <group group_id="E6">
          <title>5 mg Tadalafil</title>
          <description>The following study drugs, administered orally, once daily for 12 weeks post-randomization:
tadalafil 5-mg tablet
placebo 5-mg capsule (matching LY2452473)
placebo 10-mg tablet (matching tadalafil)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <description>Event resulted in death</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Hypertensive cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="89"/>
                <counts group_id="E6" subjects_affected="33" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Bundle branch block right</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Corneal erosion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Barrett's oesophagus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="531"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Tinea infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Corneal abrasion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Blood creatinine abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Blood insulin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Blood testosterone abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Blood urea abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Colonoscopy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Electrocardiogram qrs complex prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>High density lipoprotein decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Oestradiol increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Qrs axis abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Vitamin d deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="531"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="531"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Sensation of heaviness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Spinal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="531"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="531"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Haematospermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Varicocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Paranasal sinus hypersecretion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Sinus disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Diabetic bullosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Spider vein</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

